Nucleic acid conjugate
The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.
1. A nucleic acid conjugate having any structure represented by the following formulas 7-1 to 7-9:
wherein
X is an oligonucleotide,
L1 and L2 are each independently a sugar ligand, and
S3 is a linker.
2. The nucleic acid conjugate according to claim 1 , wherein the sugar ligand is mannose or N-acetylgalactosamine.
3. The nucleic acid conjugate according to claim 1 , wherein the oligonucleotide comprises a modified nucleotide.
4. A pharmaceutical composition comprising a nucleic acid conjugate according to claim 1 .
5. The pharmaceutical composition according to claim 4 , wherein the sugar ligand targets a liver cell.
6. The pharmaceutical composition according to claim 4 , wherein the pharmaceutical composition is a formulation suitable for intravenous or subcutaneous administration.
7. A method for treating or preventing a disease, comprising administering a nucleic acid conjugate according to claim 1 to a patient in need thereof.
8. A method for treating or preventing a disease, comprising administering a pharmaceutical composition according to claim 4 to a patient in need thereof.